Cellular genes regulated by HIV-1 infection and methods of use thereof
This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells. Other pro-apoptotic genes and methods of use thereof are also disclosed. The compositions of the invention may be used to advantage to develop novel therapeutic agents for the treatment of HIV infection. The compositions of the invention may also be used to advantage to develop novel therapeutic agents for the treatment of disorders associated with inordinate cellular apoptosis.
1. An isolated nucleic acid molecule encoding HIV-Associated Life Preserver (HALP) protein which consists of the sequence of SEQ ID NO: 1, said HALP protein having anti-apoptotic activity in HIV-1 infected cells.
2. The isolated nucleic acid molecule of claim 1 which is cDNA.
3. An isolated ribonucleic acid molecule of which is encoded by the nucleic acid molecule claim 1 .
4. The isolated nucleic acid molecule of claim 1 which is double-stranded DNA.
5. An isolated nucleic acid molecule consisting of the complement of the nucleic acid molecule of claim 1 .
6. A nucleic acid molecule which encodes an antisense molecule which consists of the entire HALP cDNA sequence of SEQ ID NO: 1 in reverse orientation.
7. A recombinant expression vector comprising a nucleic acid molecule of claim 1 .
8. The recombinant expression vector of claim 7 wherein said vector is selected from the group consisting of a plasmid, a vector, and a retroviral vector.
9. An isolated host cell transformed with an expression vector as claimed in claim 7 .
10. The isolated host cell as claimed in claim 9 , wherein said host cell is selected from the group consisting of bacteria, fungal, yeast, plant, insect, human and animal cells.
11. The isolated host cell as claimed in claim 9 , wherein said host cell is a T cell.
12. A method for identifying test compounds which decrease the anti-apoptotic activity of HALP, said method comprising:
a) providing cells which comprise the expression vector of claim 8 and which are infected with HIV-1;
b) incubating said cells in the presence and absence of a test compound, whereby said test compound enters said cells;
c) determining the number of cells undergoing apoptotic cell death relative to untreated cells, wherein an increase in the number of cells undergoing apoptotic cell death in the presence of said test compound being indicative of the ability of said test compound to decrease the anti-apoptotic activity of HALP.